American Regent, Inc.   Report issue

Contributed to NME For profit Phase 3
Founded: Shirley NY United States (1967)
Status: No NME R&D (1967)

Organization Overview

First Clinical Trial
2019
NCT04269707
First Marketed Drug
2019
selenious acid
First NDA Approval
2019
selenious acid
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

American Regent | American Regent, Inc. | AMERICAN REGENT INC

Active Ingredients

Marketed Drugs (3)

manganese sulfate (2020)

selenious acid (2019 NDA)

vasopressin (vasostrict) (2020)

Drugs in Phase 3 Trials (1)

ferric carboxymaltose (Injectafer) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Deficiency Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1